All In Biotech

Drug Trial Radar · NCT05557591

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Actual

Start

Apr 21, 2023

Primary completion

Jan 26, 2028

Study completion May 16, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects)

Conditions

  • Advanced Non-Small Cell Lung Cancer

Interventions

  • BNT116Drug

    BNT116 is administered by IV injection.

  • CemiplimabDrug

    Cemiplimab is administered Q3W by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Time frame: Up to 136 weeks from randomization

Locations

52 sites in 7 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope and Innovation

    Los Angeles, California

  • UCLA Medical Center

    Santa Monica, California

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Weill Cornell Medicine

    New York, New York

  • FirstHealth of the Carolinas Outpatient Cancer Center

    Pinehurst, North Carolina

  • Millenium Research & Clinical Development

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • LTD High Technology Hospital Medcenter

    Batumi, Georgia

  • LLC Todua Clinic

    Tbilisi, Georgia

  • LTD New Hospitals

    Tbilisi, Georgia

  • LTD Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, Georgia

  • LTD Cancer Research Centre

    Tbilisi, Georgia

  • Caucasus Medical Centre

    Tbilisi, Georgia

  • Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt

    Frankfurt, Germany

  • Universitaetsklinikum Giessen Und Marburg Gmbh Standort Giessen

    Giessen, Germany

  • Krankenhaus Martha-Maria Halle-Doelau gGmbH

    Halle, Germany

  • Klinikverbund Kempten-Oberallgäu

    Kempten, Germany

  • Staedtisches Klinikum Muenchen Bogenhausen

    München, Bavaria, Germany

  • National Cancer Center Korea

    Goyang, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Yonsei Severance

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, Gyeonggi-do, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

  • Hospital General Universitario Gregorio Marañon (HGUGM)

    Madrid, Spain

  • Clinica Universidad de Navarra - Madrid

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, Spain

  • Hospital Universitario Virgen del Rocio

    Málaga, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Instituto Valenciano de Oncologia

    Valencia, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

  • Catalan Institute of Oncology Badalona

    Badalona, Barcelona, Spain

  • Althaia Xarxa Assistencial Universitaria Manresa

    Manresa, Barcelona, Spain

  • Consorcio Hospitalario Provincial de Castellon

    Castellon, Castellon, Spain

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Taipei Tzu Chi Hospital

    New Taipei City, Taiwan

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.